Core Viewpoint - JY Health (605388.SH) announced a share reduction plan by several executives due to personal financial needs, intending to sell up to 474,900 shares, representing 0.079% of the total shares outstanding [1] Group 1: Share Reduction Plan - The share reduction plan involves executives Zhu Xiaoming, Luo Xiyue, Xiang Weibing, Cui Peng, and Guo Qin, who plan to reduce their holdings within three months after the announcement [1] - The total number of shares to be reduced is capped at 474,900, which is a small fraction of the company's total shares [1] Group 2: Executive Shareholdings - As of the announcement date, Zhu Xiaoming holds 613,218 shares (0.102% of total), Luo Xiyue holds 549,269 shares (0.091%), Xiang Weibing holds 276,134 shares (0.046%), Cui Peng holds 129,851 shares (0.022%), and Guo Qin holds 331,679 shares (0.055%) [1] Group 3: Company Background - JY Health was listed on the Shanghai Stock Exchange on August 18, 2020, with an initial issuance of 70 million shares at a price of 13.43 yuan per share [2] - The highest price recorded for the stock was 32.25 yuan on August 26, 2020, but it is currently trading below its initial offering price [2] Group 4: Financial Performance - The company raised a total of 940 million yuan from its initial public offering, with a net amount of 884 million yuan after deducting issuance costs [3] - For the year 2024, the company reported a revenue of 1.458 billion yuan, a year-on-year decrease of 10.77%, and a net loss attributable to shareholders of 29.12 million yuan [4] - The net cash flow from operating activities for 2024 was 32.65 million yuan, down 61.95% year-on-year [4]

Core Viewpoint - The company has released its 2025 semi-annual report, which includes significant financial data and operational updates, ensuring the accuracy and completeness of the information provided [1][5][20]. Company Overview - The company is identified as Hubei Junyao Health Beverage Co., Ltd., with the stock code 605388 [3]. - The board of directors and supervisory board confirm the authenticity and completeness of the report [1][3]. Financial Data - The semi-annual report includes key financial data, although specific figures are not detailed in the provided text [2]. - The company has not proposed any profit distribution or capital increase plans for this reporting period [2]. Board Meeting Details - The fifth board meeting was held on August 22, 2025, with all nine directors present, and the meeting complied with legal regulations [4][6]. - The board approved the semi-annual report and its summary during this meeting [5][6]. Supervisory Board Meeting - The fourth supervisory board meeting also took place on August 22, 2025, with all three supervisors present [14][16]. - The supervisory board confirmed the accuracy and completeness of the semi-annual report and its summary [15][16]. Major Operational Data - The company has announced its major operational data for the first half of 2025, which is yet to be detailed in the provided text [20]. - The operational data is intended to provide investors with timely insights into the company's performance [21]. Fundraising and Usage Report - The company raised a total of RMB 940.1 million through its initial public offering, with a net amount of RMB 883.56 million after expenses [21][22]. - As of June 30, 2025, the company had a balance of RMB 30.7 million in its fundraising accounts [25]. - The company has not used idle funds for cash management during the reporting period [28][29]. Compliance and Management - The company adheres to relevant laws and regulations regarding the management and use of raised funds, ensuring investor protection [23][31]. - The company has established a dedicated management system for the raised funds, including special accounts for different projects [23][24].

Key Points - The company raised a total of RMB 940.1 million through the issuance of 70 million shares at a price of RMB 13.43 per share, with a net amount of RMB 883.56 million after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of raised funds is RMB 30.7 million, after accounting for previous investments and interest income [1][2] - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations and protecting investor rights [2][3] - No idle raised funds were used to supplement working capital during the reporting period, and no funds were used for cash management [4][5] - The company has decided to extend the completion deadline for certain investment projects due to changes in market conditions and operational strategies [7][8] - The company plans to redirect unused funds from the brand upgrade project to support the bankruptcy restructuring of a subsidiary, which is expected to stabilize operations and enhance cost advantages [7][8] - The project for the new production facility in Yichang has reached its intended operational status, while the project in Zhejiang has been adjusted due to market demand uncertainties [12][14]

Fundraising Overview - The company completed the account closure for part of the special account for raised funds from its initial public offering (IPO) [1] - The company issued 70,000,000 shares at a price of RMB 13.43 per share, raising a total of RMB 940,100,000, with a net amount after expenses [1] Fund Management - The company established a fundraising management system to regulate the management and use of raised funds, ensuring investor protection [2] - The company opened multiple special accounts at different banks to manage the funds for various projects, including accounts at Bank of Communications, Shanghai Rural Commercial Bank, and Shanghai Pudong Development Bank [2][3] Account Closure - The company closed the special account at Shanghai Rural Commercial Bank, which was used for specific fundraising projects, and terminated the related three-party supervision agreement [4]

Core Viewpoint - Junyao Health reported a significant decline in both revenue and net profit for the fiscal year 2024, indicating potential challenges in its operational performance [1][3]. Financial Performance Summary - For the year 2024, the company achieved operating revenue of 1.458 billion yuan, a decrease of 10.77% compared to the previous year [1][3]. - The net profit attributable to shareholders was -29.12 million yuan, down 150.57% from 57.58 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -57.99 million yuan, a decline of 287.62% from 30.91 million yuan in the previous year [1][3]. - The net cash flow from operating activities was 32.65 million yuan, a decrease of 61.95% year-on-year [1][3]. Q1 2025 Performance Summary - In the first quarter of 2025, the company reported operating revenue of 401.48 million yuan, an increase of 1.41% year-on-year [4][6]. - The net profit attributable to shareholders was 10.91 million yuan, a decrease of 58.29% compared to the same period last year [4][6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 7.03 million yuan, down 70.46% year-on-year [4][6]. - The net cash flow from operating activities was -97.06 million yuan, compared to -129.49 million yuan in the same period last year [4][6]. Dividend Distribution Plan - The company plans to distribute a cash dividend of 0.08 yuan per share (tax included) to all shareholders, totaling approximately 46.87 million yuan [1][3].